Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE-PUK EXTEND
NCT07389460Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing rhPro-UK group with Placebo group (2 arms). Primary endpoint: Proportion of patients functionally independent (mRS score 0 to 2) at 90 days. Started Apr 2026; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07389460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389460.